Insider Selling: Athersys, Inc. (NASDAQ:ATHX) EVP Sells $47,437.25 in Stock

Athersys, Inc. (NASDAQ:ATHX) EVP John J. Harrington sold 27,107 shares of Athersys stock in a transaction on Tuesday, June 8th. The stock was sold at an average price of $1.75, for a total value of $47,437.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

ATHX stock opened at $1.62 on Friday. The stock has a market cap of $359.78 million, a P/E ratio of -3.60 and a beta of -1.67. The business has a fifty day moving average price of $1.68. Athersys, Inc. has a 1 year low of $1.40 and a 1 year high of $3.30.

Athersys (NASDAQ:ATHX) last released its earnings results on Wednesday, May 5th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.05). Research analysts forecast that Athersys, Inc. will post -0.36 earnings per share for the current year.

Separately, Zacks Investment Research downgraded Athersys from a “buy” rating to a “hold” rating in a research note on Thursday, April 22nd.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Athersys by 3.1% during the first quarter. BlackRock Inc. now owns 14,138,786 shares of the biopharmaceutical company’s stock valued at $25,451,000 after purchasing an additional 426,118 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Athersys by 36.4% during the first quarter. JPMorgan Chase & Co. now owns 3,387,931 shares of the biopharmaceutical company’s stock valued at $6,099,000 after purchasing an additional 904,899 shares in the last quarter. Geode Capital Management LLC lifted its position in Athersys by 16.2% during the first quarter. Geode Capital Management LLC now owns 3,063,396 shares of the biopharmaceutical company’s stock valued at $5,514,000 after purchasing an additional 427,666 shares in the last quarter. Citigroup Inc. raised its holdings in Athersys by 758.6% during the first quarter. Citigroup Inc. now owns 759,262 shares of the biopharmaceutical company’s stock valued at $1,367,000 after acquiring an additional 670,834 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Athersys by 3.9% during the fourth quarter. Bank of New York Mellon Corp now owns 737,928 shares of the biopharmaceutical company’s stock valued at $1,292,000 after acquiring an additional 27,860 shares during the period. Institutional investors own 26.72% of the company’s stock.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also: Moving Average (MA)

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.